Regulatory Pathways for New Antimicrobial Agents: Trade-offs to Keep the Perfect From Being the Enemy of the Good

Clinical Pharmacology and Therapeutics

Volumn 100, Issue 6, 2016, Pages 597-599

  Spellberg, B ^a   Marr, K A ^b   Brass, E P ^c  

^a LAC USC MEDICAL CENTER   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; NEW DRUG;

ANTI-INFECTIVE THERAPY; CLINICAL TRIAL (TOPIC); DRUG LEGISLATION; HOME INFUSION THERAPY; HUMAN; NOTE; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; STUDY DESIGN; UNITED STATES; WESTERN EUROPE; DRUG INDUSTRY; FOOD AND DRUG ADMINISTRATION; LEGISLATION AND JURISPRUDENCE; METHODOLOGY; PROCEDURES; RESEARCH; STANDARDS; UNCERTAINTY;

ANTI-INFECTIVE AGENTS; CLINICAL TRIALS AS TOPIC; DRUG INDUSTRY; HUMANS; RESEARCH; RESEARCH DESIGN; UNCERTAINTY; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84991490744     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1002/cpt.510     Document Type: Note

References (10)

1. Shlaes, D.M. & Moellering, R.C. Jr. The United States Food and Drug Administration and the end of antibiotics. Clin. Infect. Dis. 34, 420–422 (2002).
2. Nambiar, S., Laessig, K., Toerner, J., Farley, J. & Cox, E. Antibacterial drug development: challenges, recent developments, and future considerations. Clin. Pharmacol. Ther. 96, 147–149 (2014).
3. Wagenlehner, F.M., Umeh, O., Steenbergen, J., Yuan, G. & Darouiche, R.O. Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI). Lancet 385, 1949–1956 (2015).
4. Solomkin, J. et al. Ceftolozane/tazobactam plus metronidazole for complicated intra-abdominal infections in an era of multidrug resistance: results from a randomized, double-blind, phase 3 trial (ASPECT-cIAI). Clin. Infect. Dis. 60, 1462–1471 (2015).
5. Mazuski, J.E. et al. Efficacy and safety of ceftazidime-avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infection: results from a randomized, controlled, double-blind, phase 3 program. Clin. Infect. Dis. 62, 1380–1389 (2016).
6. Wagenlehner, F.M. et al. Ceftazidime-avibactam versus doripenem for the treatment of complicated urinary tract infections, including acute pyelonephritis: RECAPTURE, a phase 3 randomized trial program. Clin. Infect. Dis. 63, 754–762 (2016).
7. Zerbaxa (ceftolozane/tazobactam) Label. (2014).
8. Marty, F.M. et al. Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis. Lancet Infect. Dis. 16, 828–837 (2016).
9. Miceli, M.H. & Kauffman, C.A. Isavuconazole: a new broad-spectrum triazole antifungal agent. Clin. Infect. Dis. 61, 1558–1565 (2015).
10. Infectious Diseases Society of America. White paper: recommendations on the conduct of superiority and organism-specific clinical trials of antibacterial agents for the treatment of infections caused by drug-resistant bacterial pathogens. Clin. Infect. Dis. 55, 1031–1046 (2012).